ARGOS THERAPEUTICS INC | Sales 2016 | 945K 75.42M | Sales 2017 | 1.9M 152M | Capitalization | 13.18M 1.05B |
|---|---|---|---|---|---|
| Net income 2016 | -53M -4.23B | Net income 2017 | -40M -3.19B | EV / Sales 2016 | 200 x |
| Net cash position 2016 | 13.11M 1.05B | Net Debt 2017 | 4.27M 340M | EV / Sales 2017 | 9.19 x |
| P/E ratio 2016 |
-2.96
x | P/E ratio 2017 |
-0.22
x | Employees | - |
| Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 88.73% |
More Fundamentals
* Assessed data
More news
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -3.93% | 86.16B | |
| +2.76% | 40.17B | |
| -17.49% | 31.47B | |
| +54.44% | 25.24B | |
| -13.13% | 15.82B | |
| -9.12% | 11.96B | |
| -15.45% | 11.89B | |
| -42.56% | 11.61B | |
| +4.87% | 8.84B |
